See every side of every news story
Published loading...Updated

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program – DIR HONGKONG

Summary by dirhongkong.com
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA, Mar 4, 2025 – (ACN Newswire via SeaPRwire.com) – Micreos Pharmaceuticals AG (“Micreos”), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech (“NBT”), a Contract Development and Manufacturing Organization (CDMO) to develop scalable c…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dirhongkong.com broke the news in on Thursday, March 6, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.